BIONXT SOLUTIONS INC. news, videos and press releases
For more news please use our advanced search feature.
BIONXT SOLUTIONS INC. - More news...
BIONXT SOLUTIONS INC. - More news...
- BioNxt Accelerates R&D with Move to Gen-Plus Laboratory in Munich, Germany, Expanding Drug Delivery Research Capabilities
- BioNxt Solutions Expands Patent Protection for Drug Delivery Innovations Backed by Positive IPRP
- BioNxt Solutions Reports Progress on BNT23001 Development for Multiple Sclerosis Treatment
- BioNxt Solutions Announces Development of Sublingual Thin-Film for Semaglutide
- BioNxt Announces Enhanced Sublingual Product Development Pipeline with Innovative Solutions for Autoimmune Diseases and Longevity
- BioNxt Announces National Level Patent Filings for Sublingual Anticancer Drugs for the Treatment of Autoimmune Neurodegenerative Diseases
- Terry Lynch Joins BioNxt as Capital Markets Advisor
- BioNxt Provides Update on Cladribine Program for Multiple Sclerosis, Sublingual Neurodegenerative Disease Patent, and Investor Relations Activities
- BioNxt Receives Positive International Examination Report From the European Patent Office for Broad Patent Application for Sublingual Delivery of Anticancer Drugs for the Treatment of Autoimmune Neurodegenerative Diseases
- BioNxt Signs Letter of Intent with Gen-Plus GmbH & Co KG for Potential Business Collaborations
- BioNxt Signs Statement of Work with International Contract Research, Development, And Manufacturing Organization for Cladribine ODF Development
- BioNxt Signs Master Services Agreement with International Contract Research, Development, and Manufacturing Organization
